# Loss of PIK3CA Allows In Vitro Growth but Not In Vivo Progression of KRAS Mutant Lung Adenocarcinoma in a Syngeneic Orthotopic Implantation Model

**Authors:** Abigail L. Booth, Giuseppe Caso, Barbara Rosati, Ya-Ping Jiang, Wei-Xing Zong, Richard Z. Lin, Harold Bien

PMC · DOI: 10.3390/cells15060506 · 2026-03-12

## TL;DR

This study shows that while PIK3CA is not needed for KRAS mutant lung cancer cells to grow in the lab, it is crucial for tumor growth in living mice.

## Contribution

The study reveals PIK3CA's essential role in in vivo tumor progression of KRAS mutant lung cancer despite being dispensable in vitro.

## Key findings

- PIK3CA is not required for in vitro growth of KRAS mutant lung cancer cells.
- PIK3CA is essential for in vivo tumor progression in syngeneic mouse models.
- KPA cells are more sensitive to oxidative stress than KP and KPS cells.

## Abstract

Constitutively active KRAS mutations are highly prevalent in lung cancers, but the direct role of its downstream phosphatidylinositol 3-kinase (PI3K) pathway in tumor progression remains unclear. A previous study established the requirement for PIK3CA, the alpha catalytic isoform, in lung tumor development in mouse models with an intact Trp53 tumor suppressor. In this study, we further investigated the requirement of PIK3CA for tumor growth both in vitro and in vivo. We first generated a “KPA” cell line by genetically deleting Pik3ca from a murine lung adenocarcinoma “KP” cell line harboring oncogenic KrasG12D and lacking Trp53. We also examined the requirement for STK11, a tumor suppressor and metabolic regulator frequently co-mutated with KRAS in lung cancer. We found that Pik3ca is not required for cell survival and growth in vitro, even under anchorage-independent conditions, but reduced the growth rate by 15%. We next orthotopically implanted KP and KPA cells into syngeneic mice and found that PIK3CA is absolutely required for tumor progression, even in the absence of Trp53. Implantation of KP cells, or a “KPS” cell line lacking the Stk11 gene, led to rapid tumor growth and death of all host animals. In contrast, mice implanted with KPA cells all survived with no detectable lung tumors. The gene expression profiles from cultured cell lines suggest oxidative stress as a potential vulnerability of KPA cells. Indeed, we found KPA cells were more sensitive to hydrogen peroxide and diethyl maleate-induced oxidative stress as compared to KP and KPS cells. Together, these results indicate that PIK3CA is not required for lung cancer cell growth induced by mutant KRAS in vitro but is essential for in vivo progression and growth.

## Linked entities

- **Genes:** PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845], TP53 (tumor protein p53) [NCBI Gene 7157], STK11 (serine/threonine kinase 11) [NCBI Gene 6794]
- **Chemicals:** hydrogen peroxide (PubChem CID 784), diethyl maleate (PubChem CID 5271566)
- **Diseases:** lung adenocarcinoma (MONDO:0005061)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Hsp86-ps2 (heat shock protein 86, pseudogene 2) [NCBI Gene 111042] {aka 86kDa, Hsp86-3, Hsp90}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Nqo1 (NAD(P)H dehydrogenase, quinone 1) [NCBI Gene 18104] {aka Dia4, Dtd, Nmo-1, Nmo1, Nmor1, Ox-1}, STK11 (serine/threonine kinase 11) [NCBI Gene 6794] {aka LKB1, PJS, hLKB1}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Ppp1r13b (protein phosphatase 1, regulatory subunit 13B) [NCBI Gene 21981] {aka ASPP1, Tp53bp2, Trp53bp2, p85}, Kras (Kras proto-oncogene, GTPase) [NCBI Gene 16653] {aka K-Ras, K-Ras 2, K-ras, Ki-ras, Kras-2, Kras2}, Prdx1 (peroxiredoxin 1) [NCBI Gene 18477] {aka MSP23, NkefA, OSF-3, OSF3, PAG, Paga}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, Gsta1 (glutathione S-transferase, alpha 1 (Ya)) [NCBI Gene 14857] {aka Gst2-1}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Hc (hemolytic complement) [NCBI Gene 15139] {aka C5, C5a, He, Hfib2}, Pik3ca (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 18706] {aka 6330412C24Rik, caPI3K, p110, p110alpha}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, Stk11 (serine/threonine kinase 11) [NCBI Gene 20869] {aka Lkb1, Par-4}, Mgst1 (microsomal glutathione S-transferase 1) [NCBI Gene 56615] {aka 1500002K10Rik, Gst}, Mgst2 (microsomal glutathione S-transferase 2) [NCBI Gene 211666] {aka GST2, MGST-II}, Trp53 (transformation related protein 53) [NCBI Gene 22059] {aka Tp53, bbl, bfy, bhy, p44, p53}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Nfe2l2 (nuclear factor, erythroid derived 2, like 2) [NCBI Gene 18024] {aka Nrf2}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Gpx4 (glutathione peroxidase 4) [NCBI Gene 625249] {aka GPx-4, GSHPx-4, PHGPx, mtPHGPx, snGPx}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}
- **Diseases:** LUAD (MESH:D000077192), SCID (MESH:D053632), hypoxia (MESH:D000860), Cancer (MESH:D009369), weight loss (MESH:D015431), hypoxic (MESH:D002534), breast cancer (MESH:D001943), KPA (OMIM:604093), injury to (MESH:D014947), neoplastic diseases (MESH:D004194), death (MESH:D003643), lung cancer (MESH:D008175), tumorigenesis (MESH:D063646), NSCLC (MESH:D002289), pain (MESH:D010146), cytotoxic (MESH:D064420), Tumorigenicity (MESH:D002471), lung, pancreatic, colorectal, and cervical cancers (MESH:D015179), immunodeficient (MESH:D007153), pancreatic adenocarcinoma (MESH:D010190)
- **Chemicals:** taxane (MESH:C080625), blasticidin (MESH:C004500), lipid hydroperoxide (MESH:D008054), formalin (MESH:D005557), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MESH:C022616), isoflurane (MESH:D007530), phosphatidylinositol-3,4,5 triphosphate (MESH:C060974), NAD+ (MESH:D009243), ROS (MESH:D017382), paraffin (MESH:D010232), DMSO (MESH:D004121), penicillin (MESH:D010406), methylcellulose (MESH:D008747), H2O2 (MESH:D006861), Glutathione (MESH:D005978), PBS (MESH:D007854), GTP (MESH:D006160), NaF (MESH:D012969), Tween 20 (MESH:D011136), CO2 (MESH:D002245), carbohydrate (MESH:D002241), hematoxylin (MESH:D006416), sodium pyrophosphate (MESH:C003319), Trypan Blue (MESH:D014343), MTT (MESH:C070243), DEM (MESH:C014476), glucose (MESH:D005947), puromycin (MESH:D011691), NaCl (MESH:D012965), sodium deoxycholate (MESH:D003840), streptomycin (MESH:D013307), Poly(A) (MESH:D011061), AC114440050 (-), oxygen (MESH:D010100), NP-40 (MESH:C010615), phenylmethylsulfonyl fluoride (MESH:D010664), glutamine (MESH:D005973), enrofloxacin (MESH:D000077422), alcohol (MESH:D000438), SDS (MESH:D012967), formazan (MESH:D005562), ketorolac (MESH:D020910), monosaccharide (MESH:D009005), docetaxel (MESH:D000077143), Piqray (MESH:C585539), EDTA (MESH:D004492), bleomycin (MESH:D001761), lipid (MESH:D008055), HEPES (MESH:D006531), xylene (MESH:D014992), cisplatin (MESH:D002945)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** H1047R, (E) for 48, G12D
- **Cell lines:** KP — Homo sapiens (Human), Renal pelvis carcinoma, Cancer cell line (CVCL_A1IF), sc-423192 — Homo sapiens (Human), Follicular lymphoma, Cancer cell line (CVCL_1888)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025534/full.md

---
Source: https://tomesphere.com/paper/PMC13025534